News Search Results

Displaying Results 1576-1600 of 4501 "biotechnology"

Sep 03, 2025, 08:34 ET Coya Therapeutics to Participate at Upcoming September Investor Conferences

Sept. 3, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the

More news about: Coya Therapeutics, Inc.


Sep 03, 2025, 08:30 ET Patient Recruitment: Digital, Design, Data and Dedicated Support to Reach the Unreachable, Upcoming Webinar Hosted by Xtalks

the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access

More news about: Xtalks


Sep 03, 2025, 08:30 ET Overcoming IPF and Other Rare Respiratory Disease Clinical Trial Challenges, Upcoming Webinar Hosted by Xtalks

the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access

More news about: Xtalks


Sep 03, 2025, 08:00 ET Monod Bio Receives $1.5M Grant to Develop NovoBodies™ for Next-Generation Tuberculosis Diagnostics

Monod Bio, a biotechnology startup and spinout from the University of Washington's Institute for Protein Design, announced today that it has received

More news about: Monod Bio


Sep 03, 2025, 08:00 ET LenioBio partners with AffinityAI to accelerate discovery of novel complex proteins through AI-guided design and high-throughput cell-free expression

therapeutics, combining cutting-edge AI design with scalable, cell-free expression technology. About LenioBio LenioBio GmbH is a biotechnology company pioneering cell-free protein expression with its ALiCE® platform, enabling rapid discovery, development, and scalable production of proteins

More news about: LenioBio


Sep 03, 2025, 08:00 ET Andelyn Biosciences and Tern Therapeutics Partner for Late-Stage Process Performance Qualification (PPQ) Manufacturing of AAV Gene Therapy for the Treatment of CLN2 Batten Disease

andelynbio.com. About Tern Therapeutics TERN THERAPEUTICS is a privately held biotechnology company founded in 2023 with a new vision for speeding the development of transformative, one-time gene therapy medicines for rare diseases. Guided

More news about: Andelyn Biosciences


Sep 03, 2025, 08:00 ET Global Bio Conference 2025 kicks off in Seoul, charting biotech's future

Furthermore, a mentoring program, "Mentoring for Bio Youths," will be held to inspire and guide young talent who will lead the next generation of biotechnology. Minister Oh Yu-kyoung emphasized that GBC is not only a platform for global regulatory dialogue but also a critical step toward positioning

More news about: The Korea Herald


Sep 03, 2025, 07:15 ET SpliSense Reports Positive Results from Phase 2 Study of SPL84 in Cystic Fibrosis

Sept. 3, 2025 /PRNewswire/ -- SpliSense, a clinical-stage biotechnology company developing transformative RNA-based therapies for pulmonary diseases, today announced positive  results from SPL84-002, its ongoing global

More news about: SpliSense


Sep 03, 2025, 07:08 ET VLCC Unveils The Great Indian Beauty Festival 2025 - India's Biggest Beauty Celebration of the Year

booster powered by polynucleotides and the Hymagic™-4D hyaluronic acid complex for deep hydration and tissue repair, and AnteAGE MD®, a breakthrough biotechnology treatment that uses stem cell-derived growth factors and cytokines to promote skin health and rejuvenation. Speaking on the occasion, Taniya

More news about: VLCC


Sep 03, 2025, 07:00 ET Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases

Sept. 3, 2025 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma, the Company), a clinical-stage biotechnology company focused on developing next-generation siRNA therapeutics, today announced that it has entered into an additional strategic collaboration

More news about: Argo Biopharmaceutical Co., Ltd.


Sep 03, 2025, 06:30 ET Biotechnology Market is Estimated to Reach USD 6.64 Trillion by 2032 | SkyQuest Technology Consulting

LimitedBiotechnology Market Segmental Analysis Global biotechnology market is segmented by technology, cell type, therapy type, therapeutic area, and end user. By therapeutic area, the oncology segment dominated the global biotechnology market in 2024

More news about: SkyQuest Technology


Sep 03, 2025, 03:00 ET LenioBio partners with AffinityAI to accelerate discovery of novel complex proteins through AI-guided design and high-throughput cell-free expression

therapeutics, combining cutting-edge AI design with scalable, cell-free expression technology. About LenioBio LenioBio GmbH is a biotechnology company pioneering cell-free protein expression with its ALiCE® platform, enabling rapid discovery, development, and scalable production of proteins

More news about: LenioBio


Sep 02, 2025, 19:30 ET Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

LinkedIn. 5.     About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.

More news about: Eisai Inc.


Sep 02, 2025, 15:58 ET FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

LinkedIn. 5.     About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.

More news about: Eisai Inc.


Sep 02, 2025, 12:27 ET Industrial Enzymes Market Size, Trends & Growth | Projected USD 17.77 Billion by 2035 at 7.65% CAGR

biodiesel production, supporting global renewable energy goals.Enzyme Engineering & Precision Fermentation: Advances in biotechnology are leading to highly tailored enzymes with improved efficiency and stability.Expansion in Healthcare Applications: Growing use

More news about: Vantage Market Research


Sep 02, 2025, 10:43 ET Curis to Present at Upcoming Healthcare Conferences in September

Mass., Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James

More news about: Curis, Inc.


Sep 02, 2025, 10:01 ET Digital Forensics Market is Projected To Reach US$12.67 Million By 2031; at CAGR Of 11.5% | The Insight Partners

syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact

More news about: The Insight Partners


Sep 02, 2025, 09:30 ET Evommune Announces Late-Breaker Presentation of Phase 2 Data for EVO756 in Chronic Inducible Urticaria at Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

Calif., Sept. 2, 2025 /PRNewswire/ -- Evommune, Inc., a clinical stage biotechnology company discovering and developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that a full data

More news about: Evommune, Inc


Sep 02, 2025, 09:10 ET Wonderfeel's Clinical Brief Gets Published as Its Flagship Formula Earns Wellness From Within Award

Wonderfeel's Director of Research and Development, a medical doctor and clinical pharmacologist with more than 25 years of experience in pharmaceuticals, biotechnology, and medical devices. The observational data, collected through user-reported surveys, point to consistent and wide-ranging benefits:

More news about: Wonderfeel


Sep 02, 2025, 09:10 ET Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

gastrointestinal tumors are flu-like symptoms and neutropenia. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated promising results

More news about: Oncolytics Biotech® Inc.


Sep 02, 2025, 09:05 ET Robles BioCeutics Welcomes Top-Ranked Regenerative Medicine Physician Dr. Navneet Boddu to Advisory Board

Sept. 2, 2025 /PRNewswire/ -- Robles BioCeutics, a regenerative dermatology biotechnology company developing next-generation skincare solutions through stem cell-derived and senolytic technologies, is pleased to welcome Dr. Navneet

More news about: Robles BioCeutics


Sep 02, 2025, 09:01 ET AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS

automation and digital capabilities, empowering scientists with the tools and environment needed to drive scientific excellence and advancements in biotechnology. Amgen's long-standing commitment to U.S. innovation and state-of-the-art operations is reflected in more than $40

More news about: Amgen


Sep 02, 2025, 08:54 ET Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the time of management's presentation at the H.C. Wainwright 27th

More news about: Anixa Biosciences, Inc.


Sep 02, 2025, 08:30 ET Amorphical Appoints Eden Ben as CEO, as Company Advances Regulatory Pathway for Nano-Amorphous Mineral-Based Therapeutics

causes." About Amorphical Amorphical is a biotechnology company advancing a new class of nano-amorphous mineral pharmacologic agents. Leveraging a proprietary, nature-inspired platform, Amorphical aims

More news about: Amorphical


Sep 02, 2025, 08:00 ET Hemab Therapeutics Expands Leadership with Appointment of Anant Murthy, PhD, as Chief Operating Officer

Mass., Sept. 2, 2025 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the appointment of

More news about: Hemab Therapeutics


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.